Compound ID | 1790
PED-019
Class: Antisense oligonucleotide
| Spectrum of activity: | Gram-negative |
| Details of activity: | Active against Pseudomonas aeruginosa. Antisense-mediated knock-down of rspJ expression (30s ribosomal subunit protein S10) |
| Description: | Synthetic compound. The challenge of uptake and internalisation of an antisense oligonucleotide is addressed by a new porin translocation technology. |
| Institute where first reported: | Pedanius Therapeutics |
| Year first mentioned: | 2019 |
| Highest developmental phase: | Preclinical |
| Development status: | Active (as of 2022) |
| External links: | |
| Citation: | https://pedaniustherapeutics.com/pipeline |
| Patent: | WO2020109792A1 |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.